[4] Empower Pharmacy
While the data are promising, there are no indications that people with neurologic conditions should take GLP-1 medications to treat their diseases, cautions Barbara Giesser, MD, FAAN, a neurologist at the Pacific Neuroscience Institute in Santa Monica, CA
Given the strong early trial outcomes of 20-25% average weight loss, many believe Lilly will aim for a fast-track or priority review designation
SSRIs inhibit the reuptake of serotonin, allowing it to linger and continue to have a beneficial effect on mood, among other things
Patients should not attempt to stop either medication abruptly without medical guidance, as phentermine cessation can cause fatigue and mood changes, while sudden semaglutide discontinuation may trigger rebound appetite and rapid weight regain